Introduction
In a large comparative (phase III) clinical trial, subgroups of patients, as categorized by certain characteristics, usually exist, and the improvement due to the treatment often varies among patients in different subgroups. As an example, Gordon et al. [1] reported a statistically significant overall hazard ratio estimate from a randomized clinical trial in which women with ovarian cancer were treated with either pegylated liposomal doxorubicin or topotecan. For patients with platinum-sensitive disease, an even more significant estimate of hazard ratio was found. However, among patients with platnum-refractory disease, the hazard ratio was not significant. Using data from this trial, Song and Chi [2] demonstrated a two-stage procedure to test hypothesis concerning both the overall hazard ratio and subgroup-specific hazard ratio in the first stage followed by testing each individual hypothesis in the second stage. An earlier work of Follmann [3] described the PATHS (Prevention and Treatment of Hypertension Study) study [4] in which interim data yielded different treatment effect estimates among two strata ( 80-89 and 90-99 mm Hg diastolic blood pressure) of patients, and presented methods to control type I error rate when screening criterion was modified for the two strata.
When patients' characteristics are well defined, even before the trial starts, investigators may have good reasons to believe that patients in one group, say group X, will reveal better treatment outcomes than another group, say group Y, either based on scientific knowledge or empirical data from previous trials with similarly functioned drugs. Therefore, if the treatment does not look promising for patients in group X, then very unlikely it will show promising results for patients in group Y. If this is the case, we argue that a two-stage sampleenrichment trial strategy described below tends to be more ethical and cost-effective than the conventional approach, which simultaneously enrolls and randomizes patients from both groups into treatment arms. At the first stage, only patients from group X are enrolled and randomized. Treatment difference is then estimated based on data from the first stage, and only if the observed difference is promising, will patients from both groups be enrolled and randomized for the remaining part of the trial. This strategy can be viewed as a trial with early stopping for futility (see e.g., [5, 6] ). However, here, futility is only determined by data from the more promising group of patients. When the treatment shows no improvement within any groups, such design avoids further recruiting of patients from either group and is thus costeffective, and more ethically sound.
The Calcium to Prevent Preeclampsia (CPEP) trial serves well as a motivating example. The trial was a randomized, double-blind clinical trial conducted by the Division of Epidemiology, Statistics and Prevention Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development from 1992 to 1995. The principal objective of the trial was to determine if calcium supplementation in healthy pregnant nulliparae reduces the incidence of preeclampsia. A total of 4589 healthy nulliparous women who were 13-21 weeks pregnant were randomized to receive daily treatment with either 2 g of elemental calcium or placebo for the remainder of their pregnancies. The rationale, design, and methods of the trial were reported in Levine et al. [7] and the main finding that calcium supplementation did not prevent preeclampsia in healthy nulliparous women was reported in Levine et al. [8] . It is believed that, if calcium supplementation indeed can prevent preeclampsia, then the reduction in preeclampsia incidence is expected to be higher among the healthy nulliparae who normally have low calcium intake (group X) than among those who normally have higher calcium intake (group Y). In the section 'Testing the overall treatment effects', we shall use the data from the completed trial to demonstrate that, had this information been used to design the trial as a two-stage sample-enrichment trial, the trial could have been terminated with much fewer enrollments.
We will first give detailed description of the twostage sample-enrichment trial strategy and presents methods to control the type I error rate and preserve power for testing group-specific treatment effects. Details are then given on testing an overall treatment improvement indexed as a weighted average of the group-specific treatment effects. Simulation results are presented to investigate the characteristics of the tests. The methods are exemplified with data from the CPEP trial.
Fixed sample size approach
Consider a clinical trial involving two subpopulations, X $ N( X , 1) and Y $ N( Y , 1), where X and Y measure the treatment difference between the experimental treatment arm and the standard treatment arm for the two subpopulations, respectively. This paradigm provides large sample approximation for various endpoints (continuous, binary, survival, etc.) frequently encountered in clinical trials; see discussion for more details. The null hypothesis is H 0 : X ¼ 0 and Y ¼ 0, that is, there is no difference between the two treatment arms for patients from either subpopulations. For simplicity we consider one-sided alternative hypothesis, H 1 :
X > 0 or Y > 0, that is, treatment difference exists in favor of the experimental arm for at least one subpopulation.
In a fixed-size trial a sample of X 1 , . . . , X n from the X-population N( X , 1) and a sample of
Y j =m are the two sample means. The two critical values c X and c Y are chosen so that the overall type I error rate is controlled at a level of . Because observations from the two populations are independent, we have 
If there is no preference given to one subpopulation over the other in controlling the type I error rates, we may set X ¼ Y . For generality, let X ¼ ! Y (! > 0), then solving Equation (1) and noting that 0 < X , Y < 1, we have
With X and Y specified, the power of the test at X and Y is given by
The sample sizes m and n are then determined by (2) so that the power requirement is met.
Two-stage sample-enrichment approach
The two-stage sample-enrichment approach applies the treatments to a sample of patients from one subpopulation first, and if data show promising treatment effect, that is, the estimated treatment improvement exceeds certain prespecified threshold, then the treatments will be extended to all subpopulations, including the one already in the trial. Otherwise, the trial will stop for futility. To statistically formalize the concept, let X 1 , . . . , X n 1 be a sample from N( X , 1), where the sample size n 1 is a prespecified integer. If
c, then the trial will be terminated and the experimental drug will be claimed to be of no treatment difference from the standard for either group, under the assumption that X ! Y . Otherwise, we will continue to observe X n 1 þ1 , . . . , X n from N( X , 1) and
where the estimated means are derived using all available data.
Note that the null hypothesis can be rejected only if the test passes the threshold in the first stage. The type I error of such a two-stage test is thus given by
where
The two quantities, X and Y , can similarly be viewed as the corresponding type I error rate that under the sample-enrichment design the groupspecific null hypothesis is rejected when the null hypothesis is true. If we still set
,
The power of the test for rejecting either null hypothesis is given by
where ¼ n 1 /n is the ratio of the first-stage sample size to the total sample size for the X-population. Note that (4) reduces to (3) when X ¼ Y ¼ 0. The critical values, c X and c Y , and the sample sizes, n and m, need to be chosen to satisfy error requirements. Once the threshold value c for stopping after the first stage is determined, then critical values c X and c Y can be obtained from the following equations
The value of c X , however, can only be computed numerically from (4) and (5) is provided in the Appendix.)
The size n 1 and the threshold c should be reasonably determined so that a convincing decision can be made at the end of the first stage without upsetting the integrity of the study. A smaller n 1 or larger c results in a less conservative design that stops the trial more likely for futility. On the other hand, however, a larger n 1 or smaller c results in a more conservative design that makes the trial less likely to stop at the first stage for futility but may incur more cost if the treatment indeed shows no improvement. Hence n 1 and c should be chosen to balance these two scenarios. The first-stage size n 1 should be large enough so that the decision on stopping for futility is reliable, but not too large so that promising results among the X-group can be detected as early as possible and the enrichment of samples can be carried out, if indeed the treatment works better for patients in the X-group.
We present here two methods to determine the threshold value c. Note that stopping at the first stage requires that 1X c= ffiffiffiffiffi n 1 p . Thus for a given n 1 , the threshold value c can be chosen so that c= ffiffiffiffiffi n 1 p is a proportion of the smallest meaningful treatment improvement the investigators expect. For example, c= ffiffiffiffiffi n 1 p can be set to be the smallest meaningful treatment difference, or half of the difference, etc. Alternatively, c can be determined by controlling at certain level g(>) the error probability,
ÈðcÞ, of expanding the trial to include the Y-population when it should not be so. We term this probability as the false continuation probability. This gives c ¼ È À1 (1 À g). Note that this approach does not require n 1 be known.
If n 1 is not prespecified, then n 1 and c can be jointly determined by controlling both the false continuation probability and the false termination probability at certain alternative X , that is, the error probability
X Þ of stopping the trial at the first stage when the true treatment improvement is X for the X-population. If we require these two error probabilities be no more than g and , respectively, then c ¼ È
X . In the discussion section we provide some more details and rationales on how to choose g and .
Testing the overall treatment effects
A clinical trial is often based on testing hypotheses concerning the overall treatment effect, usually in the form of a weighted average of the group-specific treatment effects, that is, ¼ X þ (1 À ) Y , where 0 < < 1. In general the weight can be chosen as the sample proportion or the prevalence of the subpopulation X. The hypotheses being tested are then
With fixed sample sizes m and n that satisfy the error requirements, we reject the null hypothesis with significance level if ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
The power of the test as a function of X and Y is given by
It is noticed that the power of the fixed-size test for a weighted mean depends on X and Y through their weighted average . Thus for a fixed value of the test has the same power on the line {( X , Y ): (4) and (5) the power function of the test is found to be ð X , Y ;n,mÞ
and thus the type I error of the test is given by ð X ; n, mÞ
Unlike the fixed-size test whose power only depends on , and whose type I error is parameter free, we notice that the power of the two-stage sample-enrichment test depends on both and X , and the type I error involves one of the two mean parameters. This is not surprising since rejection of the null hypothesis relies on the estimate of X from the first-stage data. In general the sample sizes m and n are taken to satisfy sup X ( X ; n, m) , the nominal significance level.
One complication with a weighted mean as the (overall) treatment effect is its interpretation if X and Y are in opposite directions. For instance equal weights ( ¼ 1/2) and X ¼ À Y > 0 results in ¼ 0, and it is then claimed of no treatment effects. However, when restricted to group X, a significant drug benefit can be claimed. If we assume that the treatment difference in the two populations falls in the same direction, that is, X Y ! 0, then ¼ 0 if and only if X ¼ Y ¼ 0. In this case, the type I error of the two-stage enrichment design becomes parameter free.
Another implication is that the overall treatment effect involves the weight parameter , which should be approximately the population prevalence. In a classic design, all subgroups would be enrolled in proportion to their population prevalence. However, the fixed-size design allows targeted over-enrollment of one subgroup so that the sample proportion may differ from , and so may the proposed two-stage design. Thus the naive test of overall effects at the end of the two-stage design would result in biased inference. Furthermore, unbiased inference is only possible if the population value for is known or can be unbiasedly estimated from recruitment data.
It should be pointed out that if the primary clinical question is about whether the treatment works in either subgroup, then a test for groupspecific effect is preferred to a one for overall effect.
Numerical comparison of study designs
In the following we compare the fixed-size test and the sample-enrichment test, assuming both tests are at the same level of significance and have the same power under some alternative. We demonstrate that under the null hypothesis of no treatment improvement, the sample-enrichment test requires on average smaller sample sizes than the fixed-size test and thus is more cost-effective. To this end, we use the subscripts f and e to represent the fixed-size and sample-enrichment test, respectively. Thus the sample size for the fixed-size test is N f ¼ n f þ m f ¼ n f /, and the (maximum) sample size for the sample-enrichment test is N max ¼ n e þ m e ¼ n e /, where ¼ n f / (n f þ m f ) ¼ n e /(n e þ m e ). The average sample size for the enrichment test at X and Y is
We consider testing H 0 with prespecified power at the alternative X ¼ 0. 3 (1 À Y ). The sample sizes n f and m f are then computed from Equation (2) with specified values of 1 À and . For the sample-enrichment test, the threshold c is given by È À1 (1 À g) for a specified value of g. The type I errors X and Y are then obtained from Equation (3) with specified value of ! and . The critical values c X and c Y are subsequently computed from Equation (5) . Note that the sample size n 1 for the first stage is given by n e . The sample sizes n e and m e are then computed from Equation (4) with specified values of , , and . The average sample size is computed from Equation (9) . For various settings, Table 1 presents the sample sizes and the average sample sizes of the enrichment tests for ¼ 0.05 and ¼ 0.9. Clearly the average sample sizes are much smaller than the fixed sample sizes. Moreover, it is also observed that the maximal sample size in the two-stage design can be smaller than that in the fixed-size design, reflecting the increase in efficiency of the proposed design.
In order to more fully characterize design efficiency, we further examine the behavior of the bivariate power function, particularly at the alternative value of X when Y ¼ 0. The numerical results are presented in the last two columns of Table 1 , where Ã e represents the power of the enrichment design and Simulation results (data not shown) from others settings, and from testing the overall treatment improvement reveal the same conclusion.
The CPEP trial revisited
Preeclampsia, a hypertensive disorder that occurs only in women during pregnancy, may affect almost any organ system in the body, causing eclampsia, strokes, pulmonary edema, renal failure, liver dysfunction, liver rupture, coagulopathy, hemolysis, placental abruption, and other complications. Due to its importance in public health, effectively preventing preeclampsia has become a major focus in obstetrical research.
Conducted at five medical centers by the Division of Epidemiology, Statistics and Prevention Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development from 1992 to 1995, the Calcium to Prevent Preeclampsia (CPEP) trial aimed at providing a thorough evaluation of the effects of calcium supplementation for the prevention of preeclampsia in the United States.
The rationale, design, and methods of the trial were reported in Levine et al. [7] . With equal allocation, the minimum total sample size was estimated to be 4500 women, taking into consideration lost to follow-up or noncompliance. This sample size was sufficient to obtain 85% power to detect a 50% reduction in the true risk of preeclampsia among women perfectly compliant with calcium supplementation from incidence levels of at least 4% in the placebo group. Compliance was measured by counting the remaining pills in the pack and the rates were comparable for the two groups. Analysis was done by intention to treat, that is, by the groups randomized to. The main finding that calcium supplementation did not prevent preeclampsia in healthy nulliparous women was reported in Levine et al. [8] . At the end of the trial, a total of 4589 healthy women who were 13-21 weeks pregnant were equally randomized to receive daily treatment with either 2 g of elemental calcium (n ¼ 2295) or placebo (n ¼ 2294) for the remainder of their pregnancies. Excluding 296 women from the analysis due to missing preeclampsia status, the study yielded 2143 women in the calcium group with 158 cases (7.37%) of preeclampsia, as compared to 168 cases (7.81%) out of 2150 women in the placebo group, a merely 5% reduction in preeclampsia incidence rate. It thus concluded that calcium supplementation did not significantly reduce the incidence of preeclampsia (P-value¼0.6, two-sided 2 -test). Before entering the study, women may have different profile in accessing calcium supplementation, and it is believed that, if calcium supplementation indeed can help prevent preeclampsia, then the reduction in preeclampsia incidence is expected to be higher among the healthy nulliparae who normally have low calcium intake than among those who normally have high calcium intake. Indeed, this is well supported by data from the CPEP trial. Table 2 summarizes the distribution of enrolled women by treatment, calcium intake, and preeclampsia status, where the calcium intake status is based on a median cutpoint of 975 mg in the past 24 h prior to enrollment. (Women with missing status were excluded from the table.)
Among the low calcium intake group, calcium supplementation reduced preeclampsia incidence by nearly 10%, a much larger reduction as compared to only 1% among women who reported high calcium intake 24 h prior to enrollment. This information, however, was not considered at the time the CPEP trial was designed. We demonstrate below that, had this information been used to design the trial as a two-stage sample-enrichment trial, the trial could have been terminated with much fewer enrollments, and thus could have saved substantial resources. Suppose at the first stage, n 1 women who had reported low calcium intake in the past 24 h were enrolled into the trial and then subsequently equally randomized to receive either calcium supplementation or placebo. These women were then followed up and their preeclampsia status were determined. If the observed percent reduction in preeclampsia incidence rate among women receiving calcium supplementation is larger than 25% (half of the expected 50% reduction for the study) from the incidence rate among women receiving placebo, then the trial would be expanded to women who reported high calcium intake 24 h prior to enrollment. Otherwise the study will be terminated without further enrollment and calcium supplementation will be claimed to be of no help in reducing preeclampsia incidence. For various choices of n 1 , the percent reduction in preeclampsia incidence rate of calcium supplementation from placebo is presented in Table 3 . Inclusion of women into the analysis is based on their enrollment date. For example, if n 1 ¼ 1000, then we select the first 1000 women enrolled into the study who reported low calcium intake 24 h prior to the enrollment.
It is noticed that for every choice of n 1 , the observed percent reduction in preeclampsia incidence rate by calcium supplementation is substantially less than the 25% threshold, and much smaller than the expected 50% reduction. The percent reduction is expected to be even smaller among women who reported high calcium intake in the past 24 h. Therefore, if the two-stage sampleenrichment design were used, the trial would be terminated after the first stage without further enrollment.
Discussion
When heterogeneity exists among target patients in a large-scale comparative clinical trial, certain group of patients often show more improvements from the treatment than other groups of patients. Taking this information into consideration we propose in the present article a sample-enrichment design strategy to conduct the trial. The proposed design is more cost-effective if the treatment are of no difference.
Feasibility of the proposed enrichment design relies on the knowledge prior to the start of the trial that certain patients can benefit more than others Threshold sample-enrichment clinical trialgroup X will inevitably introduce bias in the maximum likelihood estimate at the end of the enrichment stage. Further research is needed to construct more efficient point and interval estimation, and p-values concerning the group-specific treatment effect ( X and Y ).
